Cargando…

Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study

Detalles Bibliográficos
Autores principales:	Cui, Yuzhong, Huang, Wei, Du, Feng, Yin, Xiaoyang, Feng, Lei, Li, Baosheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873746/ https://www.ncbi.nlm.nih.gov/pubmed/36473995 http://dx.doi.org/10.1007/s12094-022-03020-5

Ejemplares similares

Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
por: Cui, Yuzhong, et al.
Publicado: (2022)

Treatment of Alcohols with Tosyl Chloride Does Not always Lead to the Formation of Tosylates
por: Ding, Rui, et al.
Publicado: (2011)

Correction to: Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis
por: Fan, Liyuan, et al.
Publicado: (2019)

Correction to: Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis
por: Fan, Liyuan, et al.
Publicado: (2020)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Niraparib for ovarian cancer
Publicado: (2021)

Correction to: Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use
por: Lamb, Yvette N.
Publicado: (2019)

PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis
por: Feng, Lei, et al.
Publicado: (2021)

Correction to: Short‑term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
por: Wang, Zhi, et al.
Publicado: (2022)

Mannose enhances the radio-sensitivity of esophageal squamous cell carcinoma with low MPI expression by suppressing glycolysis
por: Luo, Hui, et al.
Publicado: (2022)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Impact of Crystal Habit on the Dissolution Rate and In Vivo Pharmacokinetics of Sorafenib Tosylate
por: Phan, Chi Uyen, et al.
Publicado: (2021)

A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
por: Sun, Kaiming, et al.
Publicado: (2018)

Sensitivity value of hematological markers in patients receiving chemoradiotherapy for esophageal squamous cell carcinoma
por: Zhu, Shan, et al.
Publicado: (2016)

Risk Factors Associated with Esophageal Fistula after Radiotherapy for Esophageal Squamous Cell Carcinoma
por: Hu, Bing, et al.
Publicado: (2020)

Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer
por: Zhang, Jian, et al.
Publicado: (2012)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Spontaneous conversion of O-tosylates of 2-(piperazin-1-yl)ethanols into chlorides during classical tosylation procedure
por: Kurteva, Vanya B., et al.
Publicado: (2019)

Correction for: CircRNA_100367 regulated the radiation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt3 pathway
por: Liu, Junqi, et al.
Publicado: (2021)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
por: Akce, Mehmet, et al.
Publicado: (2021)

1-Tosyl-2-[(1-tosyl-1H-benzimidazol-2-yl)methylsulfanyl]-1H-benzimidazole
por: N. Al-Mohammed, Nassir, et al.
Publicado: (2011)

Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review
por: Lian, Bi-Jun, et al.
Publicado: (2022)

Easy and direct conversion of tosylates and mesylates into nitroalkanes
por: Palmieri, Alessandro, et al.
Publicado: (2013)

Matsuda–Heck reaction with arenediazonium tosylates in water
por: Kutonova, Ksenia V, et al.
Publicado: (2015)

Imide arylation with aryl(TMP)iodonium tosylates
por: Basu, Souradeep, et al.
Publicado: (2018)

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
por: Zhang, Ling, et al.
Publicado: (2020)

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma
por: Zhang, Ling, et al.
Publicado: (2020)

Correction: PRSS8 methylation and its significance in esophageal squamous cell carcinoma
por: Bao, Yonghua, et al.
Publicado: (2017)

A Circ-0007022/miR-338-3p/Neuropilin-1 Axis Reduces the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Activating Epithelial-To-Mesenchymal Transition and PI3K/AKT Pathway
por: Zhang, Junpeng, et al.
Publicado: (2022)

Correction: Stat3 inhibitor stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma
por: Pan, Yunbao, et al.
Publicado: (2020)

Safety and management of niraparib monotherapy in ovarian cancer clinical trials
por: Monk, Bradley J, et al.
Publicado: (2023)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
por: Genther Williams, Sybil M, et al.
Publicado: (2015)

Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib
por: Liu, Caihong
Publicado: (2022)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0t0me1t9uh0kffe5blldctflh8